|The full article is available to subscribers||Subscriber Login|
The FDA has approved Yosprala (Aralez), a fixed-dose combination of delayed-release aspirin and immediate-release omeprazole, for secondary prevention of cardiovascular and cerebrovascular events in patients who are at risk of developing aspirin-associated gastric ulcers (≥55 years old or history of gastric ulcers). Yosprala is the first product to become available in the US that combines aspirin and a proton pump inhibitor (PPI).
SECONDARY PREVENTION — Aspirin irreversibly acetylates cyclooxygenase-1, blocking thromboxane synthesis and inhibiting platelet activation and aggregation for the life of the platelet (up to 10 days). It reduces the incidence of myocardial infarction by 30%, stroke by 20%, and all-cause mortality by 18% when used for secondary prevention of thromboembolic events. The annual risk of serious GI bleeding with aspirin doses ≤325 mg/day is about 0.4%, which is 2.5 times... more
- SM Weisman and DY Graham. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162:2197.
- Primary prevention of ulcers in patients taking aspirin or NSAIDs. Med Lett Drugs Ther 2010; 52:17.
- DJ Whellan et al. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. Am Heart J 2014; 168:495.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. January 5, 2017. Reprinted with permission by First Databank, Inc. All rights reserved. ©2017. www.fdbhealth.com/policies/drug-pricing-policy.
- Cost at CVS.com. Accessed January 19, 2017.